Breast density predicts endocrine treatment outcome in the adjuvant setting

被引:0
|
作者
Jack Cuzick
机构
[1] Queen Mary University of London,Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
In their report, Kim and colleagues study the ability of changes in mammographic density over a period of 12 to 18 months to predict subsequent recurrence in 1,065 Korean women with oestrogen receptor-positive breast cancer. Based on 80 recurrences, a clear gradient for lower recurrence rates was seen among women with larger density reductions - with recurrence rates being more than twofold higher in women with no reduction compared with those presenting a reduction ≥10%. This extends previous work on predicting the effectiveness of tamoxifen in individual women from the preventive setting to the adjuvant setting, and also includes women treated with aromatase inhibitors, where a slightly larger effect was seen.
引用
收藏
相关论文
共 50 条
  • [21] Teaching adjuvant endocrine breast cancer treatment to medical students
    de Visser, M.
    Fluit, C.
    Timmer-Bonte, J.
    Ottevanger, P.
    Verhagen, C.
    Klaassen, T.
    van Laarhoven, H. W. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (04): : 215 - 219
  • [22] Adjuvant endocrine therapy in human and canine breast cancer treatment
    Van Duursen, M. B. M.
    Smeets, E. E. J. W.
    Nijmeijer, S. M.
    De Jong, P. C.
    Van den Berg, M.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2012, 35 : 17 - 17
  • [23] Adjuvant endocrine treatment of breast cancer: what is the current situation?
    Kraemer, Stefan
    Thill, Marc
    Fersis, Nikos
    Maas, Nicolai
    Friedrich, Michael
    GYNAKOLOGE, 2019, 52 (05): : 354 - 359
  • [24] Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors
    Fentiman, IS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (06) : 689 - 693
  • [25] Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer
    Wassermann J.
    Rosenberg S.M.
    Current Breast Cancer Reports, 2017, 9 (2) : 100 - 110
  • [26] Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer
    Ponzone, R.
    Montemurro, F.
    Maggiorotto, F.
    Robba, C.
    Gregori, D.
    Jacomuzzi, M. E.
    Kubatzki, F.
    Marenco, D.
    Dominguez, A.
    Biglia, N.
    Sismondi, P.
    ANNALS OF ONCOLOGY, 2006, 17 (11) : 1631 - 1636
  • [27] ENDOCRINE FACTORS IN THE OUTCOME OF SYSTEMIC ADJUVANT THERAPY OF EARLY BREAST-CANCER
    BIANCO, AR
    DEPLACIDO, S
    PERRONE, F
    CARLOMAGNO, C
    DELAURENTIIS, M
    DELMASTRO, L
    LAURIA, R
    MARINELLI, A
    GALLO, C
    BREAST CANCER: FROM BIOLOGY TO THERAPY, 1993, 698 : 330 - 338
  • [28] Androgen receptor gene expression predicts endocrine treatment outcome in early-stage luminal breast cancer
    Schroth, W.
    Hoppe, R.
    Buettner, F.
    Winter, S.
    Kandabarau, S.
    Brauer, H. A.
    Fritz, P.
    Schwab, M.
    Muerdter, T. E.
    Brauch, H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S26 - S26
  • [29] Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.
    Bianchini, G.
    Pusztai, L.
    Iwamoto, T.
    Kelly, C. M.
    Zambetti, M.
    Fasolo, A.
    Del Conte, G.
    Santarpia, L.
    Symmansi, W. F.
    Gianni, L.
    CANCER RESEARCH, 2011, 71
  • [30] Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer
    Engmann, Natalie J.
    Vachon, Celine M.
    Scott, Christopher G.
    Jensen, Matthew R.
    Ma, Lin
    Brandt, Kathleen R.
    Mahmoudzadeh, Amir P.
    Malkov, Serghei
    Whaley, Dana H.
    Hruska, Carrie B.
    Wu, Fang F.
    Winham, Stacey J.
    Miglioretti, Diana L.
    Norman, Aaron D.
    Heine, John J.
    Shepherd, John
    Pankratz, V. Shane
    Kerlikowske, Karla
    CANCER RESEARCH, 2016, 76